Liminal BioSciences (NASDAQ:LMNL) Shares Up 2.5%

Liminal BioSciences Inc. (NASDAQ:LMNL – Get Rating) shot up 2.5% during trading on Tuesday . The company traded as high as $0.45 and last traded at $0.42. 19,804 shares were traded during trading, a decline of 49% from the average session volume of 38,947 shares. The stock had previously closed at $0.41.

Liminal BioSciences Stock Performance

The company has a market cap of $13.05 million, a P/E ratio of -3.23 and a beta of 1.26. The business’s 50 day simple moving average is $0.40 and its 200 day simple moving average is $0.46. The company has a current ratio of 4.85, a quick ratio of 4.85 and a debt-to-equity ratio of 0.02.

Liminal BioSciences (NASDAQ:LMNL – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted ($0.26) EPS. Sell-side analysts predict that Liminal BioSciences Inc. will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liminal BioSciences

A hedge fund recently raised its stake in Liminal BioSciences stock. Renaissance Technologies LLC grew its stake in shares of Liminal BioSciences Inc. (NASDAQ:LMNL – Get Rating) by 88.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,400 shares of the company’s stock after buying an additional 31,117 shares during the period. Renaissance Technologies LLC owned 0.21% of Liminal BioSciences worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.66% of the company’s stock.

About Liminal BioSciences

(Get Rating)

Liminal BioSciences Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases.